Research progress of antibody-drug conjugate in treatment of breast cancer

Research progress of antibody-drug conjugate in treatment of breast cancer

PDF

Shi-di ZHAO^a^,^b^,^c, Ran RAN^a^,^b^,^c, Quan-fang WANG^d, Xin-yue HANG^a^,^b^,^c, Jin YANG^a^,^b^,^c, Jiao YANG^a^,^b^,^c

Chinese Journal of New Drugs and Clinical Remedies | 2024, 43(3) : 161 - 170

Less

Chinese Journal of New Drugs and Clinical Remedies | 2024, 43(3): 161-170

• Review •

Research progress of antibody-drug conjugate in treatment of breast cancer

Full

Shi-di ZHAO^a^,^b^,^c, Ran RAN^a^,^b^,^c, Quan-fang WANG^d, Xin-yue HANG^a^,^b^,^c, Jin YANG^a^,^b^,^c, Jiao YANG^a^,^b^,^c

Affiliations

^a.Cancer Center, the First Affiliated Hospital of Xi-an Jiaotong University, Xi-an SHAANXI 710061, China

^b.Precision Medicine Center, the First Affiliated Hospital of Xi-an Jiaotong University, Xi-an SHAANXI 710061, China

^c.Department of Medical Oncology, the First Affiliated Hospital of Xi-an Jiaotong University, Xi-an SHAANXI 710061, China

^d.Department of Pharmacy, the First Affiliated Hospital of Xi-an Jiaotong University, Xi-an SHAANXI 710061, China

Published: 2024-03-25 doi: 10.14109/j.cnki.xyylc.2024.03.01

Outline

Abstract

Less

Antibody-drug conjugate （ADC）, a new type of targeted drugs for breast cancer, is formed by connecting a chemotherapeutic drug with a monoclonal antibody using a linker. The monoclonal antibody is used as a carrier to transport the chemotherapeutic drug to the specific tumor cells, thereby exerting anti-tumor effects. ADCs are classified into human epidermal growth factor receptor 2 （HER2）, human trophoblast surface antigen 2 （Trop-2）, and other molecules according to antigens that act on the different target. At present, there are three ADCs approved worldwide for the treatment of breast cancer. In addition to trastuzumab emtansine （T-DM1） and trastuzumab deruxtecan （T-DXd） for HER2-positive breast cancer, sacituzumab govitecan （SG） is beneficial for triple-negative breast cancer （TNBC）. ADCs are effective in the treatment of HER2-positive breast cancer, and also have made important progress in the treatment of advanced TNBC and some HER2 low-expressing breast cancer. These ADCs provide more options for patients with different molecular types of breast cancer.

Key words

breast neoplasms / receptor, erbB-2 / clinical study / antibody-drug conjugate

Cite this Article

Shi-di ZHAO, Ran RAN, Quan-fang WANG, Xin-yue HANG, Jin YANG, Jiao YANG. Research progress of antibody-drug conjugate in treatment of breast cancer[J]. Chinese Journal of New Drugs and Clinical Remedies, 2024 , 43 (3) : 161 -170 . DOI: 10.14109/j.cnki.xyylc.2024.03.01

Appendix

Less

Year 2024 volume 43 Issue 3

PDF

166

Cite this Article

BibTeX

Article Info

doi: 10.14109/j.cnki.xyylc.2024.03.01

Receive Date：2022-10-03
Online Date：2026-03-13
Published：2024-03-25

Article Data

Affiliations

History

Received：2022-10-03
Accepted：2023-09-26

Funding

Affiliations

^a.Cancer Center, the First Affiliated Hospital of Xi-an Jiaotong University, Xi-an SHAANXI 710061, China

^b.Precision Medicine Center, the First Affiliated Hospital of Xi-an Jiaotong University, Xi-an SHAANXI 710061, China

^c.Department of Medical Oncology, the First Affiliated Hospital of Xi-an Jiaotong University, Xi-an SHAANXI 710061, China

^d.Department of Pharmacy, the First Affiliated Hospital of Xi-an Jiaotong University, Xi-an SHAANXI 710061, China

References

Share

https://castjournals.cast.org.cn/joweb/zgxyylczz/EN/10.14109/j.cnki.xyylc.2024.03.01

Share to

Scan QR to access full text

Cite this article

BibTeX

Citations

表12种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT

Articles: Latest Articles; Most Read; Collections

Updates: Events; News; Multimedia

About: About Us

Contact

No. 86 Xueyuan South Road, Haidian District, Beijing

100081

010-62199257

qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House